The 2026 Ogawa-Yamanaka Stem Cell Prize Awarded to Jun Takahashi
Takahashi is recognized for his pioneering work translating iPS cell technology into a clinically approved therapy for Parkinson’s disease.
The Technologies We’re Developing
At Gladstone, we not only use the latest technology—we build it.
From AI models to novel vaccine approaches, our scientists are creating bleeding-edge computational tools and molecular technologies to accelerate research across every disease area. Our researchers also continue to build on iPS cells and CRISPR, technologies pioneered by scientists who now call Gladstone home, pushing even further the boundaries of what’s possible in science.
Phage Therapy
Scientists at Gladstone are developing new ways to engineer and optimize phages to counter drug-resistant infections, which represent one of the world’s most urgent health threats.
iPS Cells
One of the most important advances in modern biomedical research, iPS cells help Gladstone researchers study disease, screen drugs, and develop potential cell therapies.
Artificial Intelligence
At Gladstone, our scientists are creating some of the world’s most advanced AI models in biomedical research—allowing both experiments in living cells and AI itself to advance faster.
CRISPR Genome Editing
Gladstone researchers are using CRISPR and advancing gene-editing approaches to better understand disease, develop new diagnostics, and design next-generation therapies.
Vaccine Innovation
At Gladstone, scientists are developing innovative vaccines that generate better immune responses to respond to future pandemics and some of medicine’s greatest unmet challenges.
Related News
Read
Shinya Yamanaka Made Cells Young Again. Can That Reverse Aging?
Gladstone Investigator Shinya Yamanaka reflects on the past 20 years since his groundbreaking discovery of iPS cells and its potential to transform human health.
Read
A Revolutionary Stem-Cell Therapy Must Proceed Responsibly to Achieve its Full Potential
Gladstone Investigator Shinya Yamanaka reflects on the 20th anniversary of the discovery of iPS cells and the field’s progress toward clinical therapies.
Read
New Toolkit Turns Macrophages Into Better Cancer Fighters
Gladstone and UCSF scientists developed a method to genetically edit myeloid cells, immune cells that act as the body’s first responders.
Read
New CRISPR Screening Platform Boosts Power of Immunotherapy Against Solid Tumors
A new screening platform uncovers gene edits that enhance CAR-T cells’ ability to infiltrate and eliminate solid tumors.
Get Involved
Join the Team
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsPartner With Us
Discoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.
Learn MoreGive
Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now